India’s first homegrown mRNA COVID-19 vaccine currently under final clinical trial stages: Govt

India’s first homegrown mRNA COVID-19 vaccine is currently under final clinical trial stages, the government said on Thursday. Responding to a question at the weekly press conference, NITI Aayog Member (Health) Dr V K Paul said a candidate vaccine by Pune-based Gennova Biopharmaceuticals, which is entirely an Indian development, is in final clinical trial stages.

“We hope that it will pass that threshold that it could be used under emergency use and regular use some day,” he said.

The official noted that the vaccine can be stored in normal cold chain conditions and transported, which is a “big thing”.

“So we have a great candidate. They have also tweaked it for Omicron variant that will come forward. We need the mRNA platform because it is a new platform and it has been shown that vaccines developed on these platforms at least for coronavirus have been effective worldwide,” Paul said.

“Having an India vaccine platform is an asset in the wake of COVID-19 and Omicron, but also for other diseases for which we are still hunting for affordable, effective and lasting vaccines, so we treasure this platform and we compliment the company and the group which has gone into it. As a platform, it will be important in the near future and beyond,” he added.

ICMR Director General Balram Bhargava said this is another vaccine which really establishes that India is heading towards becoming a vaccine super-power and the fact that these vaccines are going to be available for other diseases.

“… and because such a large proportion has been vaccinated, we are not seeing such a disastrous third surge in terms of hospitalisation and mortality,” he said.

  • Related Posts

    • Pharma
    • June 24, 2025
    • 95 views
    Glenmark Pharma launches TEVIMBRA in India

    Glenmark Pharmaceuticals announced that it had launched TEVIMBRA (tislelizumab) in India after receiving approval from the Central Drugs Standard Control Organization (CDSCO). The drug is a specially designed anti-PD-1 monoclonal…

    • Pharma
    • June 24, 2025
    • 104 views
    India’s herbal and ayurvedic OTC market set to outpace global growth

    New Delhi: India’s herbal and ayurvedic OTC (over the counter) market is expected to grow at a CAGR of 6.5 per cent, from $69 million in 2025 to $118 million…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Glenmark Pharma launches TEVIMBRA in India

    Glenmark Pharma launches TEVIMBRA in India

    India’s herbal and ayurvedic OTC market set to outpace global growth

    India’s herbal and ayurvedic OTC market set to outpace global growth

    Ananda Pharma completes GMP manufacturing of MRX1 for clinical trials

    Ananda Pharma completes GMP manufacturing of MRX1 for clinical trials

    Ray of hope for HIV patients, as Hyderabad-based pharma giants secure nod for game-changing HIV drug

    Ray of hope for HIV patients, as Hyderabad-based pharma giants secure nod for game-changing HIV drug